Connect with us


New Covid-19 vaccine demonstrates ’89 efficacy’ with UK having 60m orders – Bridport and Lyme Regis News

A trial was carried out in conjunction with the UK Government’s Vaccine Taskforce.



post featured image

An experimental Covid-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.The UK has secured access to 60 million doses of the vaccine, called NVX-CoV2373.The protein-based vaccine candidate was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27% were older than 65, Novavax said.
“NVX-CoV2373 is the first vaccine…

Click here to view the original article.